{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:10:44Z","timestamp":1772165444568,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["Center Core Grant P30EY014801"],"award-info":[{"award-number":["Center Core Grant P30EY014801"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["#W81XWH-09-1-0675"],"award-info":[{"award-number":["#W81XWH-09-1-0675"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013884","name":"Macula Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To report the clinical characteristics, antibiotic susceptibilities, and review the literature of\n                      <jats:italic>Burkholderia cepacia<\/jats:italic>\n                      complex (\n                      <jats:italic>BCC<\/jats:italic>\n                      ) associated endophthalmitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Retrospective, observational case series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Clinical and microbiology records were reviewed for patients evaluated at the Bascom Palmer Eye Institute and diagnosed wisth culture-confirmed endophthalmitis due to\n                      <jats:italic>BCC<\/jats:italic>\n                      . Antibiotic susceptibility profiles were generated using standard microbiologic protocols via an automated VITEK system.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Endophthalmitis associated with\n                      <jats:italic>BCC<\/jats:italic>\n                      was diagnosed in three patients. Infection occurred in the setting of post-penetrating keratoplasty (PKP), glaucoma filtering surgery, and suspected trauma. All isolates demonstrated in vitro susceptibility to ceftazidime and meropenem. Presenting visual acuity (VA) ranged from hand motion to light perception. Initial treatment strategies included intravitreal ceftazidime (2.25\u00a0mg\/0.1\u00a0mL) and vancomycin (1.0\u00a0mg\/0.1\u00a0mL) injections with fortified topical antibiotics in 2 patients, and surgical debridement of a corneoscleral melt with patch graft along with both topical fortified antibiotics oral antibiotics in the third patient. In all 3 patients, there was no VA improvement at last follow-up, as 2 eyes ultimately underwent enucleation and 1 eye exhibited phthisis bulbi at last follow-up. BCC related endophthalmitis was reviewed among 13 reports. Treatment outcomes were generally poor and antibiotic resistance was common. These BCC isolates cases demonstrated broad resistance patterns, with susceptibilities to ceftazidime (58%), ciprofloxacin (53%), and gentamicin (33%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Endophthalmitis caused by\n                      <jats:italic>B. cepacia<\/jats:italic>\n                      is a rare clinical entity with generally poor visual outcomes despite prompt treatment with appropriate antibiotics.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12348-023-00370-1","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T09:02:24Z","timestamp":1699002144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Endophthalmitis caused by Burkholderia cepacia complex (BCC): clinical characteristics, antibiotic susceptibilities, and treatment outcomes"],"prefix":"10.1186","volume":"13","author":[{"given":"Flavius A.","family":"Beca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse D.","family":"Sengillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailey K.","family":"Robles-Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashanth G.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darlene","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas A.","family":"Yannuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry W.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"issue":"3","key":"370_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ajic.2005.01.001","volume":"33","author":"HH Balkhy","year":"2005","unstructured":"Balkhy HH, Cunningham G, Francis C, Almuneef MA, Stevens G, Akkad N, Memish ZA (2005) A National Guard outbreak of Burkholderia cepacia infection and colonization secondary to intrinsic contamination of Albuterol nebulization solution. Am J Infect Control. 33(3):182\u2013188","journal-title":"Am J Infect Control."},{"key":"370_CR2","volume-title":"ESCRS guidelines for prevention and treatment of Endophthalmitis following cataract surgery: data","author":"P Barry","year":"2013","unstructured":"Barry P, Cordov\u00e9s L, Gardner S (2013) ESCRS guidelines for prevention and treatment of Endophthalmitis following cataract surgery: data. European Society of Cataract and Refractive Surgeons, Dilemmas and Conclusions"},{"issue":"2","key":"370_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1128\/AAC.40.2.307","volume":"40","author":"JL Burns","year":"1996","unstructured":"Burns JL, Wadsworth CD, Barry JJ, Goodall CP (1996) Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agents Chemother 40(2):307\u2013313","journal-title":"Antimicrob Agents Chemother"},{"key":"370_CR4","doi-asserted-by":"publisher","unstructured":"Chen H, Zhang JJ, Xu YC, Ye JJ (2021) An unusual case report of Burkholderia cepacia endophthalmitis. Int J Ophthalmol 14(5):787\u2013790. https:\/\/doi.org\/10.18240\/ijo.2021.05.24.","DOI":"10.18240\/ijo.2021.05.24"},{"issue":"3","key":"370_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2958.1991.tb00735.x","volume":"5","author":"AD Cox","year":"1991","unstructured":"Cox AD, Wilkinson SG (1991) Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance. Mol Microbiol 5(3):641\u2013646","journal-title":"Mol Microbiol"},{"issue":"4","key":"370_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.4103\/jovr.jovr_194_16","volume":"13","author":"A Deka","year":"2018","unstructured":"Deka A, Siddique MA, Saikia SP (2018) Burkholderia cepacia Endophthalmitis: An Unusual Presentation. J Ophthalmic Vis Res 13(4):504\u2013507","journal-title":"J Ophthalmic Vis Res"},{"issue":"1","key":"370_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4103\/ijo.IJO_1035_21","volume":"70","author":"AK Deb","year":"2022","unstructured":"Deb AK, Chavan P, Kaliaperumal S, Sistla S, Madigubba H, Sarkar S, Neena A (2022) Clinical profile, visual outcome and root cause analysis of post-operative cluster endophthalmitis due to Burkholderia cepacia complex. Indian J Ophthalmol 70(1):164\u2013170","journal-title":"Indian J Ophthalmol"},{"issue":"12","key":"370_CR8","first-page":"753","volume":"17","author":"E Del Piero","year":"1985","unstructured":"Del Piero E, Pennett M, Leopold I (1985) Pseudomonas cepacia endophthalmitis. Ann Ophthalmol 17(12):753\u2013756","journal-title":"Ann Ophthalmol"},{"issue":"2","key":"370_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/jac\/42.2.153","volume":"42","author":"M Desai","year":"1998","unstructured":"Desai M, B\u00fchler T, Weller PH, Brown MR (1998) Increasing resistance of planktonic and biofilm cultures of Burkholderia cepacia to ciprofloxacin and ceftazidime during exponential growth. J Antimicrob Chemother 42(2):153\u2013160","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"370_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12941-019-0306-0","volume":"18","author":"NK Devanga Ragupathi","year":"2019","unstructured":"Devanga Ragupathi NK, Veeraraghavan B (2019) Accurate identification and epidemiological characterization of Burkholderia cepacia complex: an update. Ann Clin Microbiol Antimicrob 18(1):7","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"9","key":"370_CR11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1136\/bjo.2006.097972","volume":"90","author":"I Eser","year":"2006","unstructured":"Eser I, Altan T, Stahl JE, Aydin MD, Inan N, Kapran Z, Yilmaz OF (2006) Two cases of Burkholderia cepacia endophthalmitis. Br J Ophthalmol 90(9):1211","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"370_CR12","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1136\/bjophthalmol-2013-304129","volume":"98","author":"P Lalitha","year":"2014","unstructured":"Lalitha P, Das M, Purva PS, Karpagam R, Geetha M, Lakshmi Priya J, Naresh BK (2014) Postoperative endophthalmitis due to Burkholderia cepacia complex from contaminated anaesthetic eye drops. Br J Ophthalmol 98(11):1498\u20131502","journal-title":"Br J Ophthalmol"},{"key":"370_CR13","doi-asserted-by":"crossref","unstructured":"Lama M, Chanakya PP, Khamari B, Peketi ASK, Kumar P, Nagaraja V, Pradeep BE. Genomic and phylogenetic analysis of a multi drug resistant Burkholderia contaminans strain isolated from a patient with ocular infection. J Global Antimicrobial Resistance. 2021","DOI":"10.1016\/j.jgar.2021.04.004"},{"issue":"1","key":"370_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12348-021-00242-6","volume":"11","author":"C Lind","year":"2021","unstructured":"Lind C, Olsen K, Angelsen NK, Krefting EA, Fossen K, Gravningen K, Bertelsen G (2021) Clinical course, treatment and visual outcome of an outbreak of Burkholderia contaminans endophthalmitis following cataract surgery. J Ophthalmic Inflamm Infect. 11(1):12","journal-title":"J Ophthalmic Inflamm Infect."},{"issue":"6","key":"370_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/01.mcp.0000181475.85187.ed","volume":"11","author":"JJ Lipuma","year":"2005","unstructured":"Lipuma JJ (2005) Update on the Burkholderia cepacia complex. Curr Opin Pulm Med 11(6):528\u2013533","journal-title":"Curr Opin Pulm Med"},{"key":"370_CR16","unstructured":"Okonkwo ON, Hassan AO, Akanbi T. Burkholderia cepacia: A Cause of Post-Operative Endophthalmitis. J Eye Vision. 2019;2(1:3)"},{"key":"370_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40942-018-0138-7","volume":"4","author":"ON Okonkwo","year":"2018","unstructured":"Okonkwo ON, Hassan AO, Oderinlo O, Gyasi ME (2018) Burkholderia cepacia, a cause of post pars plana vitrectomy silicone oil related endophthalmitis: clinico-pathological presentation and outcome of management. Int J Retina Vitreous 4:35","journal-title":"Int J Retina Vitreous"},{"key":"370_CR18","doi-asserted-by":"publisher","first-page":"100977","DOI":"10.1016\/j.ajoc.2020.100977","volume":"20","author":"ON Okonkwo","year":"2020","unstructured":"Okonkwo ON, Sibanda D, Akanbi T, Hassan AO (2020) Post intravitreal bevacizumab recurrent Burkholderia cepacia endophthalmitis treated with clear lens extraction in an African. Am J Ophthalmol Case Rep 20:100977","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"Pt 11","key":"370_CR19","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1099\/jmm.0.011197-0","volume":"58","author":"K Ornek","year":"2009","unstructured":"Ornek K, Ozdemir M, Ergin A (2009) Burkholderia cepacia keratitis with endophthalmitis. J Med Microbiol 58(Pt 11):1517\u20131518","journal-title":"J Med Microbiol"},{"issue":"3","key":"370_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/sj.eye.6701501","volume":"19","author":"A Pathengay","year":"2005","unstructured":"Pathengay A, Raju B, Sharma S, Das T (2005) Recurrent endophthalmitis caused by Burkholderia cepacia. Eye (Lond) 19(3):358\u2013359","journal-title":"Eye (Lond)"},{"issue":"4","key":"370_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/jac\/dkp253","volume":"64","author":"E Peeters","year":"2009","unstructured":"Peeters E, Nelis HJ, Coenye T (2009) In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim\/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria. J Antimicrob Chemother 64(4):801\u2013809","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"370_CR22","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1128\/AAC.00946-08","volume":"53","author":"L Poirel","year":"2009","unstructured":"Poirel L, Rodriguez-Martinez JM, Pl\u00e9siat P, Nordmann P (2009) Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. Antimicrob Agents Chemother 53(3):876\u2013882","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"370_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3928\/1081597X-20121228-02","volume":"29","author":"JC Reddy","year":"2013","unstructured":"Reddy JC, Tibbetts MD, Hammersmith KM, Nagra PK, Rapuano CJ (2013) Successful management of Burkholderia cepacia keratitis after LASIK. J Refract Surg 29(1):8\u20139","journal-title":"J Refract Surg"},{"key":"370_CR24","doi-asserted-by":"crossref","unstructured":"Relhan N, Flynn HW. Endophthalmitis Caused by Gram-Negative Bacteria. In: Endophthalmitis. Singapore: Springer Singapore; 2017:185\u2013198","DOI":"10.1007\/978-981-10-5260-6_17"},{"issue":"12","key":"370_CR25","first-page":"1479","volume":"113","author":"Results of the Endophthalmitis Vitrectomy Study","year":"1995","unstructured":"Results of the Endophthalmitis Vitrectomy Study (1995) A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group Arch Ophthalmol 113(12):1479\u20131496","journal-title":"Endophthalmitis Vitrectomy Study Group Arch Ophthalmol"},{"issue":"9","key":"370_CR26","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1097\/IAE.0b013e31820a6a03","volume":"31","author":"V Sachdeva","year":"2011","unstructured":"Sachdeva V, Pathengay A, Joseph J, Sharma S, Das T (2011) Burkholderia cepacia endophthalmitis: clinico-microbiologic profile and outcomes. Retina 31(9):1801\u20131805","journal-title":"Retina"},{"key":"370_CR27","doi-asserted-by":"crossref","unstructured":"Saffra N, Moriarty E. Burkholderia cepacia endophthalmitis, in a penicillin allergic patient, following a ranibizumab injection. BMJ Case Rep. 2014;2014","DOI":"10.1136\/bcr-2013-202075"},{"issue":"22","key":"370_CR28","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.21037\/atm-2019-rcs-02","volume":"8","author":"JD Sengillo","year":"2020","unstructured":"Sengillo JD, Chen Y, Perez Garcia D, Schwartz SG, Grzybowski A, Flynn HW Jr (2020) Postoperative Endophthalmitis and Toxic Anterior Segment Syndrome Prophylaxis: 2020 Update. Ann Transl Med 8(22):1548","journal-title":"Ann Transl Med"},{"issue":"3","key":"370_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ajo.2011.08.029","volume":"153","author":"AR Shirodkar","year":"2012","unstructured":"Shirodkar AR, Pathengay A, Flynn HW Jr, Albini TA, Berrocal AM, Davis JL, Miller D (2012) Delayed- Versus Acute-Onset Endophthalmitis After Cataract Surgery. Am J Ophthalmol. 153(3):391-398 e392","journal-title":"Am J Ophthalmol."},{"issue":"11","key":"370_CR30","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1017\/ice.2021.298","volume":"43","author":"T Spilker","year":"2022","unstructured":"Spilker T, Kratholm J, Depoorter E, Vandamme P, LiPuma JJ (2022) Outbreak of Burkholderia contaminans endophthalmitis traced to a clinic ventilation system. Infect Control Hosp Epidemiol 43(11):1705\u20131707","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"11","key":"370_CR31","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1086\/598938","volume":"48","author":"R Sunenshine","year":"2009","unstructured":"Sunenshine R, Schultz M, Lawrence MG, Shin S, Jensen B, Zubairi S, Srinivasan A (2009) An outbreak of postoperative gram-negative bacterial endophthalmitis associated with contaminated trypan blue ophthalmic solution. Clin Infect Dis. 48(11):1580\u20131583","journal-title":"Clin Infect Dis."},{"key":"370_CR32","doi-asserted-by":"crossref","unstructured":"Tavares M, Kozak M, Balola A, Coutinho CP, Godinho CP, Hassan AA, . . . S\u00e1-Correia I. Adaptation and Survival of Burkholderia cepacia and B. contaminans during Long-Term Incubation in Saline Solutions Containing Benzalkonium Chloride. Front Bioengineering Biotechnol. 2020;8(630)","DOI":"10.3389\/fbioe.2020.00630"},{"key":"370_CR33","doi-asserted-by":"crossref","unstructured":"Tavares M, Kozak M, Balola A, S\u00e1-Correia I. Burkholderia cepacia complex Bacteria: a Feared Contamination Risk in Water-Based Pharmaceutical Products. Clin Microbiol Rev. 2020;33(3)","DOI":"10.1128\/CMR.00139-19"},{"issue":"9","key":"370_CR34","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1128\/IAI.00398-09","volume":"77","author":"S Uehlinger","year":"2009","unstructured":"Uehlinger S, Schwager S, Bernier SP, Riedel K, Nguyen DT, Sokol PA, Eberl L (2009) Identification of specific and universal virulence factors in Burkholderia cenocepacia strains by using multiple infection hosts. Infect Immun 77(9):4102\u20134110","journal-title":"Infect Immun"},{"key":"370_CR35","doi-asserted-by":"crossref","unstructured":"W. David Irvine, Harry W. Flynn J, Miller; D, Pflugfelder; SC. Endophthalmitis Caused by Gram-Negative Organisms. Arch Ophthalmology. 1992;110","DOI":"10.1001\/archopht.1992.01080220112031"},{"issue":"4","key":"370_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/jac\/48.4.549","volume":"48","author":"L Zhang","year":"2001","unstructured":"Zhang L, Li X-Z, Poole K (2001) Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. J Antimicrob Chemother 48(4):549\u2013552","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-023-00370-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T09:02:40Z","timestamp":1699002160000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-023-00370-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1186\/s12348-023-00370-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3181158\/v1","asserted-by":"object"}]},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Per DHHS policies as determined by the HSRO at the University of Miami, a retrospective case series of 3 patients or fewer does not meet the DHHS standard of generalizable knowledge, and therefore does not qualify the definition of research. This study was thus exempt IRB approval. Documentation attached.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed institutional consent forms.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}